Finally, Cox regression analysis of PFI showed that CKMT2 overexpression was a risk factor for CESC and LGG patients (HR > 1) but a protective factor for MESO and PRAD patients (HR < 1). Here, CKMT2 is linked to prostate adenocarcinoma.